Clinical phase 2 study to investigate the safety and efficacy of Blinatumomab in adult subjects with newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) after treatment with standard of care R-Chemotherapy. Estudio clínico de fase II que investiga la seguridad y la eficacia de blinatumomab en pacientes adultos con diagnóstico reciente de linfoma B difuso de células grandes (DLBCL) de alto riesgo después de quimioterapia-R de primera línea To evaluate the safety of blinatumomab administered after frontline R-chemotherapy in newly diagnosed subjects with high-risk DLBCL. evaluar la seguridad de blinatumomab administrado después de ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Brodalumab in Subjects with Psoriatic Arthritis To evaluate the efficacy of brodalumab, (210 mg every 2 weeks (Q2W); and 140 mg Q2W) compared to placebo, in subjects with psoriatic arthritis, as measured by the proportion of subjects achieving an A...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study to Test the Effect and Safety of Brodalumab Compared With Placebo and the Results of Stopping and Restarting Brodalumab Treatment in People with Moderate to Severe Plaque Psoriasis: AMAGINE-1 Compared with placebo: - To evaluate the efficacy of brodalumab (210 mg every 2 weeks [Q2W]; and 140 mg Q2W) in subjects with moderate to severe plaque psoriasis, as measured by the proportion of sub...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

The purpose of this study is to find out more about romosozumab in women with postmenopausal osteoporosis. This study will see if romosozumab, given in two different forms, increases bone mineral density and whether it causes any side effects. To do this, romosozumab at one concentration and in one type of syringe will be compared to romosozumab at another concentration and in another type of syringe To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab administered every month (QM) using a 90 mg/mL concentration compared with 210 mg romosozumab QM using a 70 mg/mL concentr...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to assess the tolerability and efficacy of AMG 145 in patients with hypercholesterolemia unable to tolerate an effective dose of a statin To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145, compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic subject...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to look at the effect of AMG 145 on the build up of a waxy substance (plaque) in the arteries of the heart, using a method to see inside the heart To evaluate the effect of AMG 145 on the change in burden of coronary atherosclerosis as measured by percent atheroma volume (PAV) in patients with coronary artery disease requiring angiography for a ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of the bioavailability of cinacalcet capsules compared to the approved cinacalcet tablets The primary objective of this study is to evaluate the comparative bioavailability based on AUC0-inf, AUC0-t, and Cmax, between six of the 5 mg capsules of cinacalcet swallowed whole with applesauce, ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Amgen 20050147 : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité du denosumab pour prolonger la survie sans métastases osseuses chez des hommes ayant un cancer de la prostate réfractaire aux hormones. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité du denosumab dans la prévention des métastases osseuses chez des patients ayant un cancer de la prostate ne répondant pas aux hormones. Les patients...

• Pays France
• Organes Prostate
• Spécialités Thérapies Ciblées

Amgen 20060295 : Essai de phase 1-2 évaluant l'efficacité de l'AMG655 associé à du paclitaxel et à du carboplatine,chez des patients ayant un cancer du poumon. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A Phase 1b/2 study of AMG 655 in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer.

• Pays France
• Organes Poumon, type non à petites cellules
• Spécialités Thérapies Ciblées, Chimiothérapie

AMGEN 20080579 : Essai de phase 2 évaluant l’efficacité et la tolérance de l'association du sunitinib et de l’AMG386, en traitement de première ou deuxième ligne, chez des patients ayant un carcinome à cellules rénales métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] Phase 2 open-label single-arm, multi-center study to evaluate the safety and efficacy of sunitinib malate in combination with AMG 386 as first line or second line therapy for subjects with metastatic ...

• Pays France
• Organes Rein
• Spécialités Thérapies Ciblées, Chimiothérapie